Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorSeoul National University Bundang Hospital
About this trial
Patients with type 2 diabetes and cardiovascular risk factors are at increased risk of cardiovascular events. Therefore, a multi-center prospective randomized study will be conducted to compare the efficacy and safety of cilostazol and aspirin for the prevention of major adverse cardiac and cerebrovascular events (MACCE) in high-risk patients with type 2 diabetes.
Eligibility criteria
Qualifiers
Individuals with type 2 diabetes mellitus were eligible if they were aged ≥19 years
Carotid intima-media thickness ≥ 1 mm
Ankle-brachial index < 0.9 - Pulse wave velocity ≥ 9 m/s
Flow-mediated vasodilatation < 5%
Disqualifiers
Patients with a history of major cardiovascular events, including myocardial infarction, stroke, or heart failure
Patients with heart failure (NYHA I~IV)
Patients with current active bleeding or suspected bleeding
Patients with suspected bleeding tendency or hematologic disorder, such as hemophilia or thrombocytopenia
Trial design
Treatments tested in this trial
- Cilostazol
- Aspirin
Treatment groups
1,200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov